You're using a free limited version of DrugPatentWatch: Upgrade for Complete Access

Last Updated: November 24, 2024

kynmobi Drug Patent Profile


✉ Email this page to a colleague

« Back to Dashboard


When do Kynmobi patents expire, and when can generic versions of Kynmobi launch?

Kynmobi is a drug marketed by Sumitomo Pharma Am and is included in one NDA. There are fourteen patents protecting this drug.

This drug has two hundred and fifty-four patent family members in twenty-six countries.

The generic ingredient in KYNMOBI is apomorphine hydrochloride. There are six drug master file entries for this compound. Two suppliers are listed for this compound. Additional details are available on the apomorphine hydrochloride profile page.

DrugPatentWatch® Litigation and Generic Entry Outlook for Kynmobi

A generic version of kynmobi was approved as apomorphine hydrochloride by TRUPHARMA on February 23rd, 2022.

  Sign Up

AI Research Assistant
Questions you can ask:
  • What is the 5 year forecast for kynmobi?
  • What are the global sales for kynmobi?
  • What is Average Wholesale Price for kynmobi?
Summary for kynmobi
International Patents:254
US Patents:14
Applicants:1
NDAs:1
Clinical Trials: 1
Drug Prices: Drug price information for kynmobi
Patent Litigation and PTAB cases: See patent lawsuits and PTAB cases for kynmobi
What excipients (inactive ingredients) are in kynmobi?kynmobi excipients list
DailyMed Link:kynmobi at DailyMed
Drug patent expirations by year for kynmobi
Drug Prices for kynmobi

See drug prices for kynmobi

Recent Clinical Trials for kynmobi

Identify potential brand extensions & 505(b)(2) entrants

SponsorPhase
William Ondo, MDPhase 4
SunovionPhase 4

See all kynmobi clinical trials

US Patents and Regulatory Information for kynmobi

kynmobi is protected by fourteen US patents.

Patents protecting kynmobi

Sublingual apomorphine
Patent Number: ⤷  Sign Up
Patent Expiration: ⤷  Sign Up
Patented Use: TREATMENT OF 'OFF' EPISODES IN PATIENTS WITH PARKINSON'S DISEASE

Methods of treating parkinson's disease by administration of apomorphine to an oral mucosa
Patent Number: ⤷  Sign Up
Patent Expiration: ⤷  Sign Up
Patented Use: TREATMENT OF 'OFF' EPISODES IN PATIENTS WITH PARKINSON'S DISEASE

Sublingual and buccal film compositions
Patent Number: ⤷  Sign Up
Patent Expiration: ⤷  Sign Up

Methods of treating Parkinson's disease by administration of apomorphine to an oral mucosa
Patent Number: ⤷  Sign Up
Patent Expiration: ⤷  Sign Up
Patented Use: TREATMENT OF 'OFF' EPISODES IN PATIENTS WITH PARKINSON'S DISEASE

Sublingual films
Patent Number: ⤷  Sign Up
Patent Expiration: ⤷  Sign Up
Patented Use: TREATMENT OF 'OFF' EPISODES IN PATIENTS WITH PARKINSON'S DISEASE

Sublingual films
Patent Number: ⤷  Sign Up
Patent Expiration: ⤷  Sign Up
Patented Use: TREATMENT OF 'OFF' EPISODES IN PATIENTS WITH PARKINSON'S DISEASE

Uniform films for rapid dissolve dosage form incorporating taste-masking compositions
Patent Number: ⤷  Sign Up
Patent Expiration: ⤷  Sign Up

Uniform films for rapid-dissolve dosage form incorporating anti-tacking compositions
Patent Number: ⤷  Sign Up
Patent Expiration: ⤷  Sign Up

Sublingual films
Patent Number: ⤷  Sign Up
Patent Expiration: ⤷  Sign Up
Patented Use: TREATMENT OF 'OFF' EPISODES IN PATIENTS WITH PARKINSON'S DISEASE

Sublingual apomorphine
Patent Number: ⤷  Sign Up
Patent Expiration: ⤷  Sign Up

Sublingual films
Patent Number: ⤷  Sign Up
Patent Expiration: ⤷  Sign Up
Patented Use: TREATMENT OF 'OFF' EPISODES IN PATIENTS WITH PARKINSON'S DISEASE

Sublingual apomorphine
Patent Number: ⤷  Sign Up
Patent Expiration: ⤷  Sign Up
Patented Use: TREATMENT OF 'OFF' EPISODES IN PATIENTS WITH PARKINSON'S DISEASE

Sublingual apomorphine
Patent Number: ⤷  Sign Up
Patent Expiration: ⤷  Sign Up
Patented Use: TREATMENT OF 'OFF' EPISODES IN PATIENTS WITH PARKINSON'S DISEASE

Sublingual apomorphine
Patent Number: ⤷  Sign Up
Patent Expiration: ⤷  Sign Up
Patented Use: TREATMENT OF 'OFF' EPISODES IN PATIENTS WITH PARKINSON'S DISEASE

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Exclusivity Expiration
Sumitomo Pharma Am KYNMOBI apomorphine hydrochloride FILM;SUBLINGUAL 210875-003 May 21, 2020 DISCN Yes No ⤷  Sign Up ⤷  Sign Up Y ⤷  Sign Up
Sumitomo Pharma Am KYNMOBI apomorphine hydrochloride FILM;SUBLINGUAL 210875-003 May 21, 2020 DISCN Yes No ⤷  Sign Up ⤷  Sign Up Y ⤷  Sign Up
Sumitomo Pharma Am KYNMOBI apomorphine hydrochloride FILM;SUBLINGUAL 210875-004 May 21, 2020 DISCN Yes No ⤷  Sign Up ⤷  Sign Up Y ⤷  Sign Up
>Applicant >Tradename >Generic Name >Dosage >NDA >Approval Date >TE >Type >RLD >RS >Patent No. >Patent Expiration >Product >Substance >Delist Req. >Exclusivity Expiration

Expired US Patents for kynmobi

Applicant Tradename Generic Name Dosage NDA Approval Date Patent No. Patent Expiration
Sumitomo Pharma Am KYNMOBI apomorphine hydrochloride FILM;SUBLINGUAL 210875-005 May 21, 2020 ⤷  Sign Up ⤷  Sign Up
Sumitomo Pharma Am KYNMOBI apomorphine hydrochloride FILM;SUBLINGUAL 210875-004 May 21, 2020 ⤷  Sign Up ⤷  Sign Up
Sumitomo Pharma Am KYNMOBI apomorphine hydrochloride FILM;SUBLINGUAL 210875-003 May 21, 2020 ⤷  Sign Up ⤷  Sign Up
>Applicant >Tradename >Generic Name >Dosage >NDA >Approval Date >Patent No. >Patent Expiration

International Patents for kynmobi

When does loss-of-exclusivity occur for kynmobi?

Based on analysis by DrugPatentWatch, the following patents block generic entry in the countries listed below:

Australia

Patent: 11343429
Patent: Sublingual films
Estimated Expiration: ⤷  Sign Up

Patent: 17200331
Patent: SUBLINGUAL FILMS
Estimated Expiration: ⤷  Sign Up

Patent: 19200138
Patent: SUBLINGUAL FILMS
Estimated Expiration: ⤷  Sign Up

Brazil

Patent: 2013015204
Patent: composição farmacêutica em forma de unidade de dosagem formulada para administração sublingual e uso da referida composição
Estimated Expiration: ⤷  Sign Up

Canada

Patent: 21756
Patent: FILMS SUBLINGUAUX (SUBLINGUAL FILMS)
Estimated Expiration: ⤷  Sign Up

Patent: 15370
Patent: FILMS SUBLINGUAUX COMPRENANT DE L'APOMORPHINE ET UNE BASE ORGANIQUE (SUBLINGUAL FILMS COMPRISING APOMORPHINE AND AN ORGANIC BASE)
Estimated Expiration: ⤷  Sign Up

Patent: 15378
Patent: FILMS SUBLINGUAUX COMPRENANT DE L'APOMORPHINE ET UNE BASE ORGANIQUE (SUBLINGUAL FILMS COMPRISING APOMORPHINE AND AN ORGANIC BASE)
Estimated Expiration: ⤷  Sign Up

Patent: 16942
Patent: FILMS SUBLINGUAUX COMPRENANT DE L'APOMORPHINE ET UNE BASE ORGANIQUE (SUBLINGUAL FILMS COMPRISING APOMORPHINE AND AN ORGANIC BASE)
Estimated Expiration: ⤷  Sign Up

China

Patent: 3476372
Patent: Sublingual films
Estimated Expiration: ⤷  Sign Up

Cyprus

Patent: 22988
Estimated Expiration: ⤷  Sign Up

Denmark

Patent: 51357
Estimated Expiration: ⤷  Sign Up

Eurasian Patent Organization

Patent: 1156
Patent: СУБЛИНГВАЛЬНЫЕ ПЛЕНКИ (SUBLINGUAL FILMS)
Estimated Expiration: ⤷  Sign Up

Patent: 1390855
Patent: СУБЛИНГВАЛЬНЫЕ ПЛЕНКИ
Estimated Expiration: ⤷  Sign Up

European Patent Office

Patent: 51357
Patent: FILMS SUBLINGUAUX (SUBLINGUAL FILMS)
Estimated Expiration: ⤷  Sign Up

Patent: 35988
Patent: FILMS SUBLINGUES (SUBLINGUAL FILMS)
Estimated Expiration: ⤷  Sign Up

Hong Kong

Patent: 93969
Patent: 舌下薄膜 (SUBLINGUAL FILMS)
Estimated Expiration: ⤷  Sign Up

Hungary

Patent: 49349
Estimated Expiration: ⤷  Sign Up

Israel

Patent: 5936
Patent: פילמים תת-לשוניים (Sublingual films)
Estimated Expiration: ⤷  Sign Up

Japan

Patent: 86195
Estimated Expiration: ⤷  Sign Up

Patent: 13545824
Estimated Expiration: ⤷  Sign Up

Mexico

Patent: 13006911
Patent: PELICULAS SUB-LINGUALES. (SUBLINGUAL FILMS.)
Estimated Expiration: ⤷  Sign Up

New Zealand

Patent: 2686
Patent: Sublingual films
Estimated Expiration: ⤷  Sign Up

Poland

Patent: 51357
Estimated Expiration: ⤷  Sign Up

Portugal

Patent: 51357
Estimated Expiration: ⤷  Sign Up

South Africa

Patent: 1304740
Patent: SUBLINGUAL FILMS
Estimated Expiration: ⤷  Sign Up

South Korea

Patent: 1890317
Estimated Expiration: ⤷  Sign Up

Patent: 1946774
Estimated Expiration: ⤷  Sign Up

Patent: 2025238
Estimated Expiration: ⤷  Sign Up

Patent: 2161392
Estimated Expiration: ⤷  Sign Up

Patent: 140043051
Patent: SUBLINGUAL FILMS
Estimated Expiration: ⤷  Sign Up

Patent: 180094143
Patent: 설하 필름 (Sublingual Films)
Estimated Expiration: ⤷  Sign Up

Patent: 190015597
Patent: 설하 필름 (Sublingual Films)
Estimated Expiration: ⤷  Sign Up

Patent: 190109598
Patent: 설하 필름 (Sublingual Films)
Estimated Expiration: ⤷  Sign Up

Spain

Patent: 91715
Estimated Expiration: ⤷  Sign Up

Generics may enter earlier, or later, based on new patent filings, patent extensions, patent invalidation, early generic licensing, generic entry preferences, and other factors.

See the table below for additional patents covering kynmobi around the world.

Country Patent Number Title Estimated Expiration
European Patent Office 2332523 Films uniformes pour la forme de dosage de dissolution rapide incorporant des compositions de masquage du goût (Uniform films for rapid dissolve dosage form incorporating taste-masking compositions) ⤷  Sign Up
European Patent Office 3542793 FILM MINCE DOTÉ D'UNE HÉTÉROGÉNÉITÉ UNIFORME NON AUTO-REGROUPANTE, PROCÉDÉ POUR LEUR PRODUCTION ET SYSTÈMES D'ADMINISTRATION DE MÉDICAMENTS FABRIQUÉS À PARTIR DE CEUX-CI (THIN FILM WITH NON-SELF-AGGREGATING UNIFORM HETEROGENEITY, PROCESS FOR THEIR PRODUCTION AND DRUG DELIVERY SYSTEMS MADE THEREFROM) ⤷  Sign Up
Canada 2802671 COMPOSITIONS EN FILM POUR LA DISTRIBUTION D'AGENTS ACTIFS (FILM COMPOSITIONS FOR DELIVERY OF ACTIVES) ⤷  Sign Up
>Country >Patent Number >Title >Estimated Expiration

Make Better Decisions: Try a trial or see plans & pricing

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.